Azacitidine — 100MG, Lyophilized powder for solution for injection, 1 vial

Azacitidine — 100MG, Lyophilized powder for solution for injection, 1 vial

Azacitidine is a lyophilized powder for solution for injection for intravenous; subcutaneous use. Azacitidine for Injection is a nucleoside metabolic inhibitor indicated for the treatment of patients with the following FAB myelodysplastic syndrome (MDS) subtypes: Refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL). 1.1 Myelodysplastic Syndromes (MDS) Azacitidine for Injection is indicated for treatment of patients with the following French-American-British (FAB) myelodysplastic syndrome subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transf

• Active ingredient or product type: AZACITIDINE
• Strength/concentration: 100MG
• Dosage form and route: Lyophilized powder for solution for injection, Intravenous; Subcutaneous
• Exact package presentation: 1 vial
• NDC/item number: 0143-9606-01
• Manufacturer: HIKMA PHARMACEUTICALS USA INC
• Storage/handling: Store unreconstituted vials at 20º to 25ºC (68º to 77ºF), excursions permitted to 15º to 30ºC (59º to 86ºF) [See USP Controlled Room Temperature].
• Status: Rx only

Important safety information: Anemia, Neutropenia and Thrombocytopenia: Monitor complete blood counts (CBC) frequently ( 5.1 ).

Refer to the current product labeling for complete indications, preparation or administration instructions, contraindications, warnings, precautions, and storage requirements.